Literature supports an increasing number of older patients living with neurocognitive disorders alongside with their annual worldwide costs. Therapeutic management of behavioral and psychological symptoms includes the use of anticholinergic and sedative drugs for which significant exposure is negatively associated with clinical outcomes.
Objective:
The aim of this study was to assess the healthcare costs differences related to an increase in the exposure to anticholinergic and sedative drugs in older patients with neurocognitive disorder.
Methods:
A longitudinal study was conducted during 3 years on 1,604 participants of the MEMORA cohort linked with both regional public health insurance and hospital discharge databases between 2012 and 2017. Direct medical and non-medical costs were included. Exposure to anticholinergic and sedative drugs was measured by the drug burden index (DBI).
Results:
Costs difference associated with a DBI≥0.5 were + 338€ (p < 0.001). After adjustment on comorbidities, NCD stage, cognitive impairment, functional limitation, polypharmacy, and sociodemographic characteristics, a DBI≥0.5 was found to be an independent predictor of an increase of total healthcare costs by 22%(p < 0.001).
Conclusion:
Anticholinergic and sedative drugs have a substantial economic burden among older patients with neurocognitive disorder. More studies are required to assess the clinical and economic impact of an efficient strategy based on the reduction of the exposure to anticholinergic and sedative drugs and the promotion of non-pharmacological interventions.
FriedLP, TangenCM, WalstonJ, NewmanAB, HirschC, GottdienerJ, SeemanT, TracyR, KopWJ, BurkeG, McBurnieMA, Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci56, M146–156.
3.
MontamatSC, CusackBJ, VestalRE (1989) Management of drug therapy in the elderly. N Engl J Med321, 303–309.
GurwitzJH, FieldTS, HarroldLR, RothschildJ, DebellisK, SegerAC, CadoretC, FishLS, GarberL, KelleherM, BatesDW (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA289, 1107–1116.
6.
ChanM, NicklasonF, VialJH (2001) Adverse drug events as a cause of hospital admission in the elderly. Intern Med J31, 199–205.
7.
PassarelliMCG, Jacob-FilhoW, FiguerasA (2005) Adverse drug reactions in an elderly hospitalised population: Inappropriate prescription is a leading cause. Drugs Aging22, 767–777.
8.
SultanaJ, CutroneoP, TrifiròG (2013) Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother4, S73–S77.
9.
FieldTS, GilmanBH, SubramanianS, FullerJC, BatesDW, GurwitzJH (2005) The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care43, 1171–1176.
10.
HohlCM, NosykB, KuramotoL, ZedPJ, BrubacherJR, Abu-LabanRB, ShepsSB, SobolevB (2011) Outcomes of emergency department patients presenting with adverse drug events. Ann Emerg Med58, 270–279.e4.
11.
MeierF, MaasR, SonstA, PatapovasA, MüllerF, Plank-KiegeleB, PfistermeisterB, SchöffskiO, BürkleT, DormannH (2015) Adverse drug events in patients admitted to an emergency department: An analysis of direct costs. Pharmacoepidemiol Drug Saf24, 176–186.
12.
MukkuSSR, SinhaP, SivakumarPT, VargheseM (2020) Anticholinergic burden among hospitalised older adults with psychiatric illnesses- a retrospective study. Curr Drug Saf.
13.
CrossAJ, GeorgeJ, WoodwardMC, AmesD, BrodatyH, WolfeR, ConnorsMH, ElliottRA (2017) Potentially inappropriate medication, anticholinergic burden, and mortality in people attending memory clinics. J Alzheimers Dis60, 349–358.
14.
DauphinotV, FaureR, OmraniS, GoutelleS, BourguignonL, Krolak-SalmonP, MouchouxC (2014) Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: An elderly inpatient, multicenter cohort. J Clin Psychopharmacol34, 565–570.
15.
McMichaelAJ, ZafeiridiE, RyanM, CunninghamEL, PassmoreAP, McGuinnessB (2020) Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging Ment Health, doi: 10.1080/13607863.2020.1830028.
16.
BerdotS, BertrandM, DartiguesJ-F, FourrierA, TavernierB, RitchieK, AlpérovitchA (2009) Inappropriate medication use and risk of falls –A prospective study in a large community-dwelling elderly cohort. BMC Geriatr9, 30.
17.
HilmerSN, MagerDE, SimonsickEM, CaoY, LingSM, WindhamBG, HarrisTB, HanlonJT, RubinSM, ShorrRI, BauerDC, AbernethyDR (2007) A drug burden index to define the functional burden of medications in older people. Arch Intern Med167, 781–787.
18.
WilsonNM, HilmerSN, MarchLM, CameronID, LordSR, SeibelMJ, MasonRS, ChenJS, CummingRG, SambrookPN (2011) Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc59, 875–880.
19.
GnjidicD, CummingRG, Le CouteurDG, HandelsmanDJ, NaganathanV, AbernethyDR, HilmerSN (2009) Drug Burden Index and physical function in older Australian men. . Br J Clin Pharmacol68, 97–105.
20.
GnjidicD, Le CouteurDG, AbernethyDR, HilmerSN (2012) Drug burden index and beers criteria: Impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol52, 258–265.
21.
GnjidicD, BellJS, HilmerSN, LönnroosE, SulkavaR, HartikainenS (2012) Drug Burden Index associated with function in community-dwelling older people in Finland: A cross-sectional study. Ann Med44, 458–467.
22.
WilsonNM, HilmerSN, MarchLM, CameronID, LordSR, SeibelMJ, SambrookPN (2010) Associations between drug burden index and physical function in older people in residential aged care facilities. Age Ageing39, 503–507.
23.
HilmerSN, MagerDE, SimonsickEM, LingSM, WindhamBG, HarrisTB, ShorrRI, BauerDC, AbernethyDR, Health ABC Study (2009) Drug burden index score and functional decline in older people. Am J Med122, 1142–1149.e1–2.
24.
GnjidicD, Le CouteurDG, NaganathanV, CummingRG, CreaseyH, WaiteLM, SharmaA, BlythFM, HilmerSN (2012) Effects of drug burden index on cognitive function in older men. J Clin Psychopharmacol32, 273–277.
25.
LowryE, WoodmanRJ, SoizaRL, HilmerSN, MangoniAA (2012) Drug burden index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol52, 1584–1591.
26.
NishtalaPS, NarayanSW, WangT, HilmerSN (2014) Associations of drug burden index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiol Drug Saf23, 753–758.
27.
GnjidicD, HilmerSN, HartikainenS, TolppanenA-M, TaipaleH, KoponenM, BellJS (2014) Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer’s disease: A national population cohort study. PloS One9, e83224.
28.
GnjidicD, HilmerSN, BlythFM, NaganathanV, CummingRG, HandelsmanDJ, McLachlanAJ, AbernethyDR, BanksE, Le CouteurDG (2012) High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther91, 521–528.
29.
LönnroosE, GnjidicD, HilmerSN, BellJS, KautiainenH, SulkavaR, HartikainenS (2012) Drug Burden Index and hospitalization among community-dwelling older people. Drugs Aging29, 395–404.
30.
Alzheimer’s Disease International (2019) World Alzheimer Report 2019. Attitudes to dementia. Alzheimer’s Disease International, London.
31.
DauphinotV, MoutetC, RouchI, VerdurandM, MouchouxC, Delphin-CombeF, GaujardS, Krolak-SalmonP, MEMORA group (2019) A multicenter cohort study to investigate the factors associated with functional autonomy change in patients with cognitive complaint or neurocognitive disorders: The MEMORA study protocol. BMC Geriatr19, 191.
32.
SloaneP, IveyJ, RothM, RoedererM, WilliamsCS (2008) Accounting for the sedative and analgesic effects of medication changes during patient participation in clinical research studies: Measurement development and application to a sample of institutionalized geriatric patients. Contemp Clin Trials29, 140–148.
33.
LinjakumpuT, HartikainenS, KlaukkaT, KoponenH, KiveläS-L, IsoahoR (2003) A model to classify the sedative load of drugs. Int J Geriatr Psychiatry18, 542–544.
34.
TaipaleHT, HartikainenS, BellJS (2010) A comparison of four methods to quantify the cumulative effect of taking multiple drugs with sedative properties. Am J Geriatr Pharmacother8, 460–471.
35.
DuránCE, AzermaiM, Vander SticheleRH (2013) Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol69, 1485–1496.
36.
SalahudeenMS, DuffullSB, NishtalaPS (2015) Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatr15, 31.
37.
TuneLE (2001) Anticholinergic effects of medication in elderly patients. J Clin Psychiatry62Suppl 21, 11–14.
38.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
39.
LawtonMP, BrodyEM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist9, 179–186.
40.
CortaredonaS, VentelouB (2017) The extra cost of comorbidity: Multiple illnesses and the economic burden of non-communicable diseases. BMC Med15, 216.
41.
LiuY, DeA (2015) Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. Int J Stat Med Res4, 287–295.
42.
FaureR, DauphinotV, Krolak-SalmonP, MouchouxC (2013) A standard international version of the Drug Burden Index for cross-national comparison of the functional burden of medications in older people. J Am Geriatr Soc61, 1227–1228.
43.
MacNeil-VroomenJL, ThompsonM, Leo-SummersL, MarottoliRA, Tai-SealeM, AlloreHG (2020) Health-care use and cost for multimorbid persons with dementia in the National Health and Aging Trends Study. Alzheimers Dement16, 1224–1233.
44.
CostaN, WübkerA, De MauléonA, ZwakhalenSMG, ChallisD, Leino-KilpiH, HallbergIR, StephanA, ZabaleguiA, SaksK, MolinierL, WimoA, VellasB, SauerlandD, BinotI, SotoME, RightTimePlaceCare consortium (2018) Costs of care of agitation associated with dementia in 8 European countries: Results from the RightTimePlaceCare Study. J Am Med Dir Assoc19, 95.e1–95.e10.
45.
LeibsonCL, LongKH, RansomJE, RobertsRO, HassSL, DuhigAM, SmithCY, EmersonJA, PankratzVS, PetersenRC (2015) Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population-based study. Alzheimers Dement11, 917–932.
46.
Billioti de GageS, BégaudB, BazinF, VerdouxH, DartiguesJ-F, PérèsK, KurthT, ParienteA (2012) Benzodiazepine use and risk of dementia: Prospective population based study. BMJ345, e6231.
47.
GraySL, DublinS, YuO, WalkerR, AndersonM, HubbardRA, CranePK, LarsonEB (2016) Benzodiazepine use and risk of incident dementia or cognitive decline: Prospective population based study. BMJ352, i90.
48.
Billioti de GageS, MorideY, DucruetT, KurthT, VerdouxH, TournierM, ParienteA, BégaudB (2014) Benzodiazepine use and risk of Alzheimer’s disease: Case-control study. BMJ349, g5205.
49.
SaastamoinenLK, VerhoJ (2015) Register-based indicators for potentially inappropriate medication in high-cost patients with excessive polypharmacy. Pharmacoepidemiol Drug Saf24, 610–618.
50.
HagstromK, NailorM, LindbergM, HobbsL, SobierajDM (2015) Association between potentially inappropriate medication use in elderly adults and hospital-related outcomes. J Am Geriatr Soc63, 185–186.
51.
SköldungerA, FastbomJ, WimoA, FratiglioniL, JohnellK (2015) Impact of inappropriate drug use on hospitalizations, mortality, and costs in older persons and persons with dementia: Findings from the SNAC Study. Drugs Aging32, 671–678.
52.
WalkerV, PatelH, KurlanderJL, EssoiB, YangJ, MahableshwarkarAR, SampJC, AkhrasKS (2015) Association between cognitive function and health care costs 3 months and 6 months after initiating antidepressant medication for depressive disorders. J Manag Care Spec Pharm21, 742–752.
53.
LaceyL, BobulaJ, NieckoT, LeibmanC (2017) Informal care time and cost in a large clinical trial sample of patients with mild to moderate Alzheimer’s disease: Determinants and level of change observed. Neurol Ther6, 11–23.
54.
PrinceM, BryceR, AlbaneseE, WimoA, RibeiroW, FerriCP (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement9, 63–75.e2.
55.
MoriartyF, CahirC, BennettK, FaheyT (2019) Economic impact of potentially inappropriate prescribing and related adverse events in older people: A cost-utility analysis using Markov models. BMJ Open9, e021832.
56.
NakhamA, MyintPK, BondCM, NewlandsR, LokeYK, CruickshankM (2020) Interventions to reduce anticholinergic burden in adults aged 65 and older: A systematic review. J Am Med Dir Assoc21, 172–180.e5.
